Trial · NCT07910747
Effects of Taurine Supplementation and Morning or Evening High-intensity Exercise on Circadian Clock Genes and Inflammatory Parameters in Adult Women With Obesity
NCT07910747, Not applicable, Not yet recruiting, University of Sao Paulo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Taurine Supplementation and Morning or Evening High-intensity Exercise on Circadian Clock Genes and Inflammatory Parameters in Adult Women With Obesity. Trials, record NCT07910747. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910747
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Taurine Supplementation and Morning or Evening High-intensity Exercise on Circadian Clock Genes and Inflammatory Parameters in Adult Women With Obesity
- NCT number
- NCT07910747
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- University of Sao Paulo
- Conditions
- Obesity (Disorder), Inflammation
- Interventions
- Taurine supplementation, Placebo Supplementation, High-intensity interval training (HIIT)
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in diurnal variation of BMAL1 gene expression in peripheral blood mononuclear cells (PBMCs) | Baseline (Week 0) and post-intervention (Week 12). | Diurnal variation in BMAL1 gene expression will be assessed in PBMCs before and after interventions using quantitative polymerase chain reaction (qPCR). Gene expression will be quantified in morning (7:00 AM) and evening (7:00 PM) samples, and diurnal variation will be calculated as the difference between evening and morning relative gene expression levels. |
| Secondary | Changes in diurnal variation of CLOCK gene expression in peripheral blood mononuclear cells (PBMCs) | Baseline (Week 0) and post-intervention (Week 12). | Diurnal variation in CLOCK gene expression will be assessed in PBMCs before and after interventions using quantitative polymerase chain reaction (qPCR). Gene expression will be quantified in morning (7:00 AM) and evening (7:00 PM) samples, and diurnal variation will be calculated as the difference between evening and morning relative gene expression levels. |
| Secondary | Changes in diurnal variation of PER genes expression in peripheral blood mononuclear cells (PBMCs) | Baseline (Week 0) and post-intervention (Week 12). | Diurnal variation in PER1 and PER2 genes expression will be assessed in PBMCs before and after interventions using quantitative polymerase chain reaction (qPCR). Gene expression will be quantified in morning (7:00 AM) and evening (7:00 PM) samples, and diurnal variation will be calculated as the difference between evening and morning relative gene expression levels. |
| Secondary | Changes in diurnal variation of CRY genes expression in peripheral blood mononuclear cells (PBMCs) | Baseline (Week 0) and post-intervention (Week 12). | Diurnal variation in CRY1 and CRY2 genes expression will be assessed in PBMCs before and after interventions using quantitative polymerase chain reaction (qPCR). Gene expression will be quantified in morning (7:00 AM) and evening (7:00 PM) samples, and diurnal variation will be calculated as the difference between evening and morning relative gene expression levels. |
| Secondary | Changes in diurnal variation of NR1D1 gene expression in peripheral blood mononuclear cells (PBMCs) | Baseline (Week 0) and post-intervention (Week 12). | Diurnal variation in NR1D1 gene expression will be assessed in PBMCs before and after interventions using quantitative polymerase chain reaction (qPCR). Gene expression will be quantified in morning (7:00 AM) and evening (7:00 PM) samples, and diurnal variation will be calculated as the difference between evening and morning relative gene expression levels. |
| Secondary | Changes in BMAL1 protein expression in peripheral blood mononuclear cells (PBMCs) | Baseline (Week 0) and post-intervention (Week 12). | Changes in BMAL1 protein expression in PBMCs will be assessed before and after the intervention using Western Blotting. Protein expression will be quantified in morning (7:00 AM) and evening (7:00 PM) samples by densitometric analysis. |
| Secondary | Changes in CLOCK protein expression in peripheral blood mononuclear cells (PBMCs) | Baseline (Week 0) and post-intervention (Week 12). | Changes in CLOCK protein expression in PBMCs will be assessed before and after the intervention using Western Blotting. Protein expression will be quantified in morning (7:00 AM) and evening (7:00 PM) samples by densitometric analysis. |
| Secondary | Changes in PER proteins expression in peripheral blood mononuclear cells (PBMCs) | Baseline (Week 0) and post-intervention (Week 12). | Changes in PER1 and PER2 proteins expression in PBMCs will be assessed before and after the intervention using Western Blotting. Protein expression will be quantified in morning (7:00 AM) and evening (7:00 PM) samples by densitometric analysis. |
| Secondary | Changes in CRY proteins expression in peripheral blood mononuclear cells (PBMCs) | Baseline (Week 0) and post-intervention (Week 12). | Changes in CRY1 and CRY2 proteins expression in PBMCs will be assessed before and after the intervention using Western Blotting. Protein expression will be quantified in morning (7:00 AM) and evening (7:00 PM) samples by densitometric analysis. |
| Secondary | Changes in NR1D1 protein expression in peripheral blood mononuclear cells (PBMCs) | Baseline (Week 0) and post-intervention (Week 12). | Changes in NR1D1 protein expression in PBMCs will be assessed before and after the intervention using Western Blotting. Protein expression will be quantified in morning (7:00 AM) and evening (7:00 PM) samples by densitometric analysis. |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910747
GET https://conductscience.org/api/trials/v1/NCT07910747/registered?page=2